4. Significant Strategic Drug Development Collaborations (Details Narrative) - USD ($) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2017 |
Dec. 31, 2016 |
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Licenses Revenue | $ 7,500,000 | $ 0 |
| Milestone revenue | 0 | 3,000,000 |
| Research, development, license and supply agreement [Member] | Shire [Member] | ||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Licenses Revenue | $ 7,500,000 | |
| Milestone revenue | $ 3,000,000 | |
| Percent ownership in Xenetic | 4.70% | |
| License and supply agreements [Member] | Serum Institute of India Ltd [Member] | ||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Milestone revenue | $ 0 | |
| Percent ownership in Xenetic | 7.20% | 7.50% |
| License and supply agreements [Member] | Pharmsynthez [Member] | ||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Percent ownership in Xenetic | 61.50% | 52.60% |
| X | ||||||||||
- Definition Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|